This safety study comprises a dose escalation study of VOY-101, followed by a cohort of subjects randomized to the maximum tolerated dose arm, a lower dose arm, and control arm.
1 Primary · 0 Secondary · Reporting Duration: Through 24 months
Active Control
Experimental Treatment
Non-Treatment Group
45 Total Participants · 7 Treatment Groups
Primary Treatment: Mid Dose · Has Placebo Group · Phase 1 & 2
Age 18+ · All Participants · 8 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you: